Notice Number: NOT-NS-09-018
Release Date: September 22, 2009
National Institute of Neurological Disorders and Stroke (NINDS) (http://www.ninds.nih.gov)
The National Institute of Neurological Disorders and Stroke (NINDS) intends to issue a Program Announcement with Special Referral Considerations (PAR) in the fall of 2009 to provide support for exploratory and developmental translational research on therapeutics for reducing mortality and morbidity caused by acute exposures to chemical threat agents. Chemical threat agents are toxic chemicals that could be released by a deliberate terrorist attack against civilians, or by accident or natural disaster causing mass casualties. The NIH CounterACT Research Program supports basic, translational, and clinical research aimed at the discovery and/or identification of better therapeutic medical countermeasures against chemical threat agents, and facilitates their movement through the regulatory process (www.ninds.nih.gov/counteract).
CounterACT Exploratory/Developmental Projects in Translational Research (R21) will be utilized to support 1-2 year pilot studies to generate tools and proof-of-principle data for therapeutics to treat exposures to chemical threats. Chemical threats include traditional chemical warfare nerve agents such as sarin and VX, toxic industrial chemicals such as cyanide and chlorine, and toxic agricultural chemicals such as parathion and sodium fluoroacetate. Pilot studies may include the creation and validation of screening assays for therapy development, identification of candidate therapeutics, and development of preliminary proof-of-principle data on the efficacy of candidate therapeutics. Four to six awards are anticipated, each with a direct costs limit of $250,000 per year.
It is anticipated that several other NIH Institutes, including the National Eye Institute (NEI), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Environmental Health Sciences (NIEHS), and the National Institute of General Medical Sciences (NIGMS), may also participate in this funding opportunity announcement.
This notice is being provided to allow potential applicants sufficient time to develop responsive projects.
APPLICATIONS ARE NOT BEING REQUESTED AT THIS TIME.
Direct inquiries regarding this Notice to:
David A. Jett, Ph.D.
Program Director, NIH CounterACT Research
National Institutes of Health, NINDS
6001 Executive Blvd.
NSC, Room 2177, MSC 9527
Bethesda, MD 20892-9527
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Office of Extramural
National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
Department of Health
and Human Services (HHS)